242 related articles for article (PubMed ID: 16767907)
1. Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Aitini E; Marangolo M
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):51-7. PubMed ID: 16767907
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial chemotherapy for unresectable pancreatic cancer.
Cantore M; Pederzoli P; Cornalba G; Fiorentini G; Guadagni S; Miserocchi L; Frassoldati A; Ceravolo C; Smerieri F; Muchmore JH
Ann Oncol; 2000 May; 11(5):569-73. PubMed ID: 10907950
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience.
Mambrini A; Sanguinetti F; Pacetti P; Caudana R; Iacono C; Guglielmi A; Guadagni S; Del Freo A; Fiorentini G; Cantore M
In Vivo; 2006; 20(6A):751-5. PubMed ID: 17203761
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
Mambrini A; Bassi C; Pacetti P; Torri T; Iacono C; Ballardini M; Orlandi M; Guadagni S; Fiorentini G; Cantore M
Pancreas; 2008 Jan; 36(1):56-60. PubMed ID: 18192882
[TBL] [Abstract][Full Text] [Related]
8. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
11. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732
[TBL] [Abstract][Full Text] [Related]
12. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
[TBL] [Abstract][Full Text] [Related]
16. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E
J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study.
Kurtz JE; Kohser F; Négrier S; Trillet-Lenoir V; Walter S; Limacher JM; Untereiner M; Kayitalire L; Jaeck D; Dufour P
Hepatogastroenterology; 2000; 47(35):1450-3. PubMed ID: 11100374
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Oztop I; Yilmaz U; Yavuzsen T; Yaren A; Tarhan O; Sagol O; Coker A; Alakavuklar M
Chemotherapy; 2004 Jun; 50(3):127-32. PubMed ID: 15282439
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
